Buy PALI Ahead of ASCENTRA-UC Dosing Start - High-Risk, Asymmetric Biotech Play
Palisade Bio is a small-cap clinical-stage biotech with PALI-2108 - an oral, gut-targeted PDE4 inhibitor prodrug - moving into a global Phase 2b (ASCENTRA-UC) after Health Canada CTA clearance and recent Phase 1b data presented at UEG Week. The balance sheet and enterprise value leave room for upside should early signals or enrollment news show tra…